Regeneron Pharmaceuticals REGN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's financing cash flow?
- Regeneron Pharmaceuticals (REGN) reported financing cash flow of -$802.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's financing cash flow changed year-over-year?
- Regeneron Pharmaceuticals's financing cash flow increased by 26.3% year-over-year, from -$1.09B to -$802.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's financing cash flow?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's financing cash flow has grown at a 54.4% compound annual growth rate (CAGR), from -$1.01B to -$3.72B.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.